These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 29095654)

  • 1. Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US.
    Franklin M; Burns L; Perez S; Yerragolam D; Makenbaeva D
    Curr Med Res Opin; 2018 Feb; 34(2):353-360. PubMed ID: 29095654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.
    Trivedi D; Landsman-Blumberg P; Darkow T; Smith D; McMorrow D; Mullins CD
    J Manag Care Spec Pharm; 2014 Oct; 20(10):1006-15. PubMed ID: 25278323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Nilotinib With Cardiovascular Diseases in Patients With Chronic Myelogenous Leukemia: A National Population-Based Cohort Study.
    Huang CE; Lee KD; Chang JJ; Tzeng HE; Huang SH; Yu LH; Chen MC
    Oncologist; 2024 Jan; 29(1):e81-e89. PubMed ID: 37561957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of monthly prescription cap on medication persistence among patients with hypertension, hyperlipidemia, or diabetes.
    Wang CC; Wei D; Farley JF
    J Manag Care Pharm; 2013 Apr; 19(3):258-68. PubMed ID: 23537460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The incidence and prevalence of diabetes mellitus and related atherosclerotic complications in Korea: a National Health Insurance Database Study.
    Koo BK; Lee CH; Yang BR; Hwang SS; Choi NK
    PLoS One; 2014; 9(10):e110650. PubMed ID: 25329714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Longitudinal Activity Measures and Diabetes Risk: An Analysis From the National Institutes of Health All of Us Research Program.
    Perry AS; Annis JS; Master H; Nayor M; Hughes A; Kouame A; Natarajan K; Marginean K; Murthy V; Roden DM; Harris PA; Shah R; Brittain EL
    J Clin Endocrinol Metab; 2023 Apr; 108(5):1101-1109. PubMed ID: 36458881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinship analysis of type 2 diabetes mellitus familial aggregation in Taiwan.
    Liao PJ; Ting MK; Kuo CF; Ding YH; Lin CM; Hsu KH
    Biomed J; 2023 Aug; 46(4):100549. PubMed ID: 35863666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in Diabetes Medication Taking and Incidence of Depression in Patients with Type 2 Diabetes: A Retrospective Cohort Study from 2010 to 2018.
    Chou LN; Raji MA; Yu X; Kuo YF
    Int J Behav Med; 2024 Apr; 31(2):192-201. PubMed ID: 36952218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of physical disability on the risk of gastric cancer incidence in elderly patients with diabetes: a focus on regional disparity.
    Choi M; Lee WR; Han KT; Kim W
    Cancer Causes Control; 2024 Apr; 35(4):705-710. PubMed ID: 38066202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of pancreatitis with risk of diabetes: analysis of real-world data.
    Ba DM; Chinchilli VM; Cozzi AM; Bradley DP; Pichardo-Lowden AR
    Front Clin Diabetes Healthc; 2023; 4():1326239. PubMed ID: 38264059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incident Cancer Risk in Patients with Incident Type 2 Diabetes Mellitus in Hungary (Part 1).
    Abonyi-Tóth Z; Rokszin G; Fábián I; Kiss Z; Jermendy G; Kempler P; Lengyel C; Wittmann I; Molnár GA; Sütő G
    Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends and Patterns of Urodynamic Studies in U.S. Males, 2000-2012.
    Conover MM; Jonsson Funk M; Kinlaw AC; Borawski KM; Wu JM
    PLoS One; 2015; 10(7):e0133657. PubMed ID: 26196514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hemorrhage risk of dasatinib therapy.
    Pontarollo G; Reinhardt C
    Blood; 2023 Jun; 141(24):2917-2918. PubMed ID: 37318908
    [No Abstract]   [Full Text] [Related]  

  • 14. Hyperlipidemia-Attributed Deaths in the U.S. in 2018-2021.
    Zheutlin AR; Harris BRE; Stulberg EL
    Am J Prev Med; 2024 Jun; 66(6):1075-1077. PubMed ID: 38408688
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.
    Takaku T; Iriyama N; Mitsumori T; Sato E; Gotoh A; Kirito K; Noguchi M; Koike M; Sakamoto J; Oba K; Komatsu N
    Oncology; 2018; 94(2):85-91. PubMed ID: 29151104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis.
    Iriyama N; Sugimoto KJ; Sato E; Takaku T; Tokuhira M; Nakazato T; Ishikawa M; Fujita H; Fujioka I; Kimura Y; Asou N; Kizaki M; Komatsu N; Hatta Y; Kawaguchi T
    Med Oncol; 2018 Sep; 35(11):142. PubMed ID: 30194496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib.
    Cole AL; Wood WA; Muluneh B; Lund JL; Elston Lafata J; Dusetzina SB
    JCO Oncol Pract; 2020 May; 16(5):e443-e455. PubMed ID: 32196424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nilotinib-Induced Diabetes Mellitus in a Young Female with Chronic Myeloid Leukemia.
    Ismail AS; Yassin MA
    Cureus; 2020 Sep; 12(9):e10277. PubMed ID: 33042713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia.
    Minson AG; Cummins K; Fox L; Costello B; Yeung D; Cleary R; Forsyth C; Tatarczuch M; Burbury K; Motorna O; Shortt J; Fleming S; McQuillan A; Schwarer A; Harrup R; Holmes A; Ratnasingam S; Chan KL; Hsu WH; Ashraf A; Putt F; Grigg A
    Blood Adv; 2019 Apr; 3(7):1084-1091. PubMed ID: 30944100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors.
    Wang Y; Travers RJ; Farrell A; Lu Q; Bays JL; Stepanian A; Chen C; Jaffe IZ
    PLoS One; 2023; 18(11):e0294438. PubMed ID: 37983208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.